Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems to ...
Alnylam's lead candidate for ATTR-CM, Amvuttra (vutrisiran), has shown promising results in the HELIOS-B clinical trial. The top-line data demonstrated a significant reduction in mortality ...
She emphasized the positive results of the HELIOS-B Phase 3 study, regulatory filings for vutrisiran in ATTR cardiomyopathy, and the company's transition to profitability with $95 million in non ...
M, consensus $809.95M. Discover the Best Stocks and Maximize Your Portfolio: See what stocks are receiving strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback